Valeant Pharmaceuticals Announces Management And Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Valeant Pharma (VRX) Twitter Bull Throws in the Towel
February 29, 2016 1:34 PM ESTA notable Valeant Pharma (NYSE: VRX) bull on Twitter appears to be throwing in the towel.
Truth about Valeant said: "Valeant is certainly giving their best impression of a house of cards on the verge of collapse. We can no longer defend this... More
TD Securities Downgrades Valeant Pharmaceuticals (VRX) to Hold
February 29, 2016 8:19 AM ESTTD Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold with a price target of $110.00 (from $155.00). The change follows news the company has withdrawn guidance.
"We are downgrading Valeant to HOLD from Buy to reflect the reduced visibility into F2016 outlook. The downgrade... More
Valeant Pharma (VRX) Confirms Paragraph IV Patent Challenge of Salix's Xifaxan
February 29, 2016 6:10 AM ESTValeant Pharma (NYSE: VRX) confirms that its wholly owned subsidiary, Salix Pharmaceuticals, has received a notice letter dated February 11, 2016 from Actavis Laboratories FL, Inc. (Actavis) stating that the U.S. Food and Drug Administration (FDA) has received Actavis' Abbreviated New Drug Application (ANDA) containing a... More
